Posted by Michael Wonder on 28 Sep 2020
Enhertu approved in Japan for the treatment of patients with HER2 positive metastatic gastric cancer
25 September 2020 - Approval of SAKIGAKE designated medicine is based on pivotal phase 2 DESTINY-Gastric01 trial and represents second approval for Enhertu in Japan within six months.
Daiichi Sankyo today announced the approval of Enhertu (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate, in Japan for the treatment of patients with HER2 positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
